Search

Your search keyword '"Pusterla, L"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Pusterla, L" Remove constraint Author: "Pusterla, L"
69 results on '"Pusterla, L"'

Search Results

1. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

2. Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024

3. What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

4. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

5. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

6. Treatment of patients with chronic hepatitis C infection in Lombardia: A report by the Lombardia Hepatitis Network

9. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

10. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

11. Risk factors for lipodystrophy in the CISAI cohort

12. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: A randomized multicentric study

13. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study

14. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity

15. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

16. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

17. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

18. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

19. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

20. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

21. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

22. Economic evaluation of HIV treatments: The I.CO.N.A. cohort study

23. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

24. HIV and metabolic syndrome - A comparison with the general population

25. Lo studio di coorte I.CO.N.A. (Italian CohOrt Naive Antiretrovirals): caratteristiche all’arruolamento dei primi 1676 soggetti

26. Osteonecrosis in protease inhibitor-treated patients

27. Cause and effect relationship of drug adverse events: Our experience using protease inhibitors of HIV [Relazione di causalità delle reazioni avverse a farmaci: Un'esperienza nell'utilizzo degli inibitori della proteasi di HIV]

28. HAART tolerability: Post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients

29. Prevalence of the Metabolic Syndrome in HIV Patients

32. Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

33. Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart

34. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

35. The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

36. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

37. Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

38. Cause and effect relationship of drug adverse events: Our experience using protease inhibitors of HIV | Relazione di causalità delle reazioni avverse a farmaci: Un'esperienza nell'utilizzo degli inibitori della proteasi di HIV

40. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

41. Treatment of patients with chronic hepatitis C infection in Lombardia: A report by the Lombardia Hepatitis Network

42. Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy

44. What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

45. HIV and metabolic syndrome: a comparison with the general population

46. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

47. Risk factors for lipodystrophy in the CISAI cohort

48. Osteonecrosis in protease inhibitor-treated patients

49. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group

50. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity

Catalog

Books, media, physical & digital resources